BC
INSY

Broadfin Capital’s Insys Therapeutics, Inc. INSY Stock Holding History

Broadfin Capital’s Portfolio INSY Stock Details INSY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-900,000
Closed -$4.15M – 62
2013
Q2 		$4.15M Buy
+900,000
New +$3.3M 0.81% 31

Other funds holding INSY

CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
BA
BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
EMFAT
Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.06B AUM 106.87% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Broadfin Capital's INSY Position: Q3 2013 in Review

Broadfin Capital sold out of Insys Therapeutics, Inc. (INSY) in Q3 2013, closing a stake of 900,000 shares — an estimated $4.15M sold.

Broadfin Capital first reported a position in INSY in Q2 2013 and held it in 1 quarter. The position peaked at $4.15M in Q2 2013. 71 funds tracked by Wall St. Rank hold INSY as of Q3 2013.

  • Broadfin Capital reported no remaining Insys Therapeutics, Inc. position as of Q3 2013 after selling out during the quarter.
  • Broadfin Capital sold 900,000 Insys Therapeutics, Inc. shares in Q3 2013, an estimated $4.15M.
  • Broadfin Capital first reported a position in Insys Therapeutics, Inc. in Q2 2013 and held it in 1 quarter.
  • Broadfin Capital's Insys Therapeutics, Inc. position peaked at $4.15M in Q2 2013.
  • 71 funds tracked by Wall St. Rank held Insys Therapeutics, Inc. as of Q3 2013.

Based on Broadfin Capital's 13F filing for Q3 2013, filed 14 Nov 2013.